Skip to content
Dark
Search
Subscribe
Follow on LinkedIn
Home
About Us
Biotech & Life Sciences
Drug Discovery
Fortune
Sustainability
Second Opinion
Press Releases
Archive
November 2025
5:
FDA approvals - October 2025
November 2025
4:
How Epicrispr are leading the first epigenetic editing trial for muscular dystrophy
November 2025
2:
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
October 2025
31:
Perspective Therapeutics to Participate in Upcoming November Conferences
October 2025
30:
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
October 2025
30:
Saama Unveils Industry-first AI-Powered Tables, Listings, and Figures (TLF) Analyzer to Transform Clinical Study Reporting
October 2025
30:
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
October 2025
29:
Seer to Participate in Upcoming November Investor Conferences
October 2025
29:
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
October 2025
29:
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference
October 2025
29:
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
October 2025
28:
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th
October 2025
28:
Verily Accelerates Precision Health AI With NVIDIA
October 2025
27:
Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025
October 2025
27:
Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights
October 2025
26:
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
October 2025
26:
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025
October 2025
25:
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
October 2025
25:
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
October 2025
24:
Lilly to Acquire Adverum Biotechnologies
October 2025
24:
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
October 2025
23:
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
October 2025
23:
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
October 2025
23:
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
October 2025
22:
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
October 2025
21:
Four years of progression-free survival: Nuvation Bio’s new standard in lung cancer
October 2025
20:
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2025
20:
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
October 2025
20:
Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025
October 2025
17:
Verily Launches a New Consumer Health App, Verily Me, at HLTH USA 2025
October 2025
16:
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
October 2025
16:
Seer to Report Third Quarter 2025 Financial Results on November 6, 2025
October 2025
16:
Avidity Biosciences to Participate in Upcoming Investor Conference
October 2025
16:
Belite Bio to Participate in the 2025 Maxim Growth Summit
October 2025
15:
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
October 2025
15:
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 2025
15:
FDA approvals - September 2025
October 2025
15:
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
October 2025
14:
SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months
October 2025
14:
Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
October 2025
14:
Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal’s Sellersville, Pennsylvania Site
October 2025
14:
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
October 2025
14:
Affinia Therapeutics to Participate in Upcoming Investor Conferences
October 2025
14:
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
October 2025
14:
Verily, UCHealth, University of Colorado Anschutz, and RefinedScience launch strategic collaboration for AI-powered research and care transformation
October 2025
13:
Excellergy Debuts with $70 Million Series A Financing to Advance First-in-Class Portfolio of Trifunctional Effector Cell Response Inhibitors (ECRIs) for Complete Allergic Control
October 2025
13:
From stealth to spotlight: with $70m Series A, ‘total allergic control’ is Excellergy's goal
October 2025
13:
Geron Corporation Announces Executive Leadership Transitions and Appointments
October 2025
13:
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
October 2025
10:
Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025
October 2025
10:
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2025
9:
New CEO of Kindbody David Stern is in the business of building families
October 2025
8:
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
October 2025
8:
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
October 2025
7:
A Legend in the making: how Ying Huang is scaling CAR-T to global markets
October 2025
7:
Affinia Therapeutics Announces Series C Financing to Advance New Class of Gene Therapies Intended to Provide Improved Safety and Efficacy
October 2025
7:
From sickness to prevention: How welfare cuts risk undermining the UK's 10-Year Health Plan
October 2025
6:
Moloch and Medicine: why good intentions built a broken system, and why CGT might fix it all (sort of)
October 2025
6:
Aspect Biosystems to Present at 2025 Cell & Gene Meeting on the Mesa
October 2025
6:
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society
October 2025
6:
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
October 2025
3:
Breaking the bottleneck: why Oklo’s bet on Atomic Alchemy could change cancer care
October 2025
3:
MassBio 2025 Patient Advocacy Summit: Purpose, In Spite of Pressure
October 2025
2:
A Bushel of Change: Digitizing the Grain Supply Chain
October 2025
2:
Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
October 2025
2:
When is JPM Week 2026?
October 2025
2:
Ocugen to Present at Industry and Investor Conferences in October 2025
October 2025
1:
Engines, Excipients, and Everyday Essentials: Elizabeth Grove on Lubrizol’s Sustainability Role
October 2025
1:
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 2025
30:
One Trash Can, Infinite Possibilities: The Future of Recycling According to AMP
September 2025
30:
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
September 2025
30:
MassBio Statement on President Trump’s announcement on most-favored-nation pricing
September 2025
29:
Saama Introduces Modular and Adaptive AI Agents For Clinical Innovation
September 2025
29:
Why Every Gigafactory Needs a Recycling Plant Next Door
September 2025
29:
FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company’s Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer
September 2025
26:
Finding balance in the noise
September 2025
26:
ThredUp: Scaling Second-Hand for a Sustainable Future
September 2025
25:
From Strengthening Fleets to Smart Ships: Navigating Tanker Cycles with Ardmore
September 2025
25:
Sick enough: the silent struggles of sub-clinical illness in modern medicine
September 2025
25:
In the Company of Shadows: Love, Labour, and the Long Way Through
September 2025
24:
Electricity Designed for the Future: EDF power solutions’ Tristan Grimbert on Competing in North America’s Toughest Energy Market
September 2025
24:
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States
September 2025
24:
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
September 2025
23:
PowerTrack and Stem, Inc.’s Push for Renewable Confidence
September 2025
23:
Advanced Clinical Announces Leadership Transition
September 2025
22:
Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors
September 2025
22:
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
September 2025
22:
Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration
September 2025
22:
Capital With Conviction: How Khosla Ventures Walks With Founders for 10x Impact
September 2025
22:
MassBio and Google empower biotech workers with AI for Drug Discovery Training
September 2025
19:
Not Just Net Zero: Why B Corps Must Lead the Charge on Equity and Emissions
September 2025
18:
How AI, Carbon Markets, and Co-Ops Are Changing the Economics of Farming
September 2025
18:
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 2025
18:
Launching the Palmetto Beacon Venture Fellowship: Building a stronger investor ecosystem
September 2025
18:
Gut Feelings: Harnessing the Gut Microbiome to Manage Anxiety in Primary Care
September 2025
17:
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
September 2025
17:
Feeding the Future: Inside Aurélio Pavinato’s Big Dream for Agriculture
September 2025
17:
Cellares Selects Five Best-in-Class Technology Providers, Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences and AltemisLab, to Expand Cell Q’s Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality Control
September 2025
16:
Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
September 2025
16:
SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial
